NO963344L - Peptider gjenkjent ved melanoma-spesifikke cytotoksiske lymfocytter og anvendelse derav - Google Patents

Peptider gjenkjent ved melanoma-spesifikke cytotoksiske lymfocytter og anvendelse derav

Info

Publication number
NO963344L
NO963344L NO963344A NO963344A NO963344L NO 963344 L NO963344 L NO 963344L NO 963344 A NO963344 A NO 963344A NO 963344 A NO963344 A NO 963344A NO 963344 L NO963344 L NO 963344L
Authority
NO
Norway
Prior art keywords
melanoma
peptides
specific cytotoxic
cytotoxic lymphocytes
peptides recognized
Prior art date
Application number
NO963344A
Other languages
English (en)
Norwegian (no)
Other versions
NO963344D0 (no
Inventor
Craig L Slingluff
Victor H Engelhart
Donald F Hunt
Jeffrey Shabanowitz
Andrea L Cox
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26892817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO963344(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of NO963344D0 publication Critical patent/NO963344D0/no
Publication of NO963344L publication Critical patent/NO963344L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO963344A 1994-02-16 1996-08-09 Peptider gjenkjent ved melanoma-spesifikke cytotoksiske lymfocytter og anvendelse derav NO963344L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19739994A 1994-02-16 1994-02-16
US08/234,784 US6660276B1 (en) 1994-02-16 1994-04-29 Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
PCT/US1995/001991 WO1995022561A2 (fr) 1994-02-16 1995-02-16 Peptides reconnus par les lymphocytes cytotoxiques specifiques du melanome, et applications

Publications (2)

Publication Number Publication Date
NO963344D0 NO963344D0 (no) 1996-08-09
NO963344L true NO963344L (no) 1996-10-14

Family

ID=26892817

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963344A NO963344L (no) 1994-02-16 1996-08-09 Peptider gjenkjent ved melanoma-spesifikke cytotoksiske lymfocytter og anvendelse derav

Country Status (9)

Country Link
US (1) US6660276B1 (fr)
EP (1) EP0745095A1 (fr)
AU (1) AU701531B2 (fr)
CA (1) CA2182889C (fr)
FI (1) FI963196L (fr)
MX (1) MX9603431A (fr)
NO (1) NO963344L (fr)
NZ (1) NZ282183A (fr)
WO (1) WO1995022561A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
WO1995029193A2 (fr) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Antigenes du melanome
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
NZ291153A (en) 1994-07-25 1999-01-28 Boehringer Mannheim Gmbh Determination of a specific antibody using multiple antigens containing several epitope regions which react with the antibody
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
CA2243235C (fr) * 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapie utilisant des lymphocytes t cytotoxiques (ctl)
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
AU712820B2 (en) * 1996-03-19 1999-11-18 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytotoxic lymphocytes, and uses therefor
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
ES2456666T3 (es) 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
EP1633387B1 (fr) * 2003-06-17 2012-02-22 Mannkind Corporation Combinaisons d'antigenes associes a des tumeurs dans des compositions pour divers types de cancers
WO2006037059A2 (fr) 2004-09-27 2006-04-06 The Johns Hopkins Universtiy Systeme de spectrometrie de masse de point d'intervention
ES2413079T3 (es) 2005-06-17 2013-07-15 Mannkind Corporation Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral
US7993638B2 (en) * 2006-03-01 2011-08-09 Janssen Pharmaceutica Nv Cancer treatment combining lymphodepleting agent with CTLs and cytokines
CN116987174A (zh) * 2023-07-26 2023-11-03 百蓁生物技术(武汉)有限公司 一种pHLA复合物裂解液及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
WO1986006487A1 (fr) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Methode de determination de mimotopes
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
AU6496094A (en) 1993-03-31 1994-10-24 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US5472856A (en) * 1993-12-21 1995-12-05 Immunobiology Research Institute, Inc. Recombinant human thymopoietin proteins and uses therefor
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
FI963196A0 (fi) 1996-08-15
WO1995022561A2 (fr) 1995-08-24
NZ282183A (en) 1998-07-28
EP0745095A1 (fr) 1996-12-04
US6660276B1 (en) 2003-12-09
FI963196A7 (fi) 1996-10-15
WO1995022561A3 (fr) 1996-03-07
NO963344D0 (no) 1996-08-09
CA2182889A1 (fr) 1995-08-24
AU701531B2 (en) 1999-01-28
MX9603431A (es) 1997-03-29
FI963196L (fi) 1996-10-15
AU1921595A (en) 1995-09-04
CA2182889C (fr) 2008-12-23

Similar Documents

Publication Publication Date Title
WO1995022561A3 (fr) Peptides reconnus par les lymphocytes cytotoxiques specifiques du melanome, et applications
GR3036951T3 (en) Cells with multiple altered epitopes on a surface antigen for use in transplantation
PL347977A1 (en) Novel methods for therapeutic vaccination
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
AU6597998A (en) HLA-A2.1 binding peptides and their uses
EP1189624A4 (fr) Peptides de liaison a hla et leurs utilisations
BRPI9912175B8 (fr)
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
EP4411376A3 (fr) Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie
EP0531401A4 (en) Enhancing the association of exogenous peptides with class i mhc molecules on immune system cells
WO2004022590A3 (fr) Glycopeptides muc1 immunogenes
Asai et al. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins
Zhang et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous α fetoprotein in mice
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
AU4577899A (en) Hla binding peptides and their uses
Price et al. Induction of immunity to chemically-induced rat tumours by cellular or soluble antigens
PT996636E (pt) Antigenio ha-1
Binz et al. Partial characterization of cell surface idiotypes on alloantigen‐activated T lymphoblasts
Johnson et al. Identification of prostatic acid phosphatase (PAP) specific HLA‐DR1‐restricted t‐cell epitopes
ES2061731T3 (es) Procedimiento de extraccion de antigenos de membrana con propiedades inmunogenicas de celulas neoplasicas humanas y los productos asi obtenidos.
EP3055322B1 (fr) Protéines ubiquitinées
WO2023137370A3 (fr) Vaccins contre le sars-cov-2 à base de cellules autologues
Are Mage-3 and Influenza-Matrix
Srivastava Heat-Shock-Protein-Based Vaccines against Cancers and Intracellular Infections
YU24401A (sh) Novi postupci za terapeutsku vakcinaciju

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application